Undisclosed Degrader (ABM Program)
Colorectal Cancer
PreclinicalActive
Key Facts
About Captor Therapeutics
Captor Therapeutics leverages its proprietary Optigrade™ platform to discover and develop novel therapeutics based on Targeted Protein Degradation (TPD), a revolutionary approach to address high unmet medical needs. The company, with R&D labs in Wroclaw, Poland, and business operations in Basel, Switzerland, has secured over €76 million in non-dilutive grant funding for its R&D projects. Its pipeline includes a first-in-class MCL-1 degrader for resistant cancers and programs in colorectal cancer and autoimmune diseases, positioning it as a key European player in the competitive TPD field.
View full company profileTherapeutic Areas
Other Colorectal Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CY-101 + Pembrolizumab | Cytovation | Phase 1/2 |
| LONSURF | Otsuka Holdings | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| Botensilimab + Balstilimab | Agenus | Phase 2 |